Protein C Osaka 10 with Aberrant Propeptide Processing: Loss of Anticoagulant Activity Due to an Amino Acid Substitution in the Protein C Precursor

Summary

We studied the molecular basis of protein C deficiency in a family with a history of thromboembolic disease. An approximately 50% reduction in anticoagulant activity despite normal levels of protein C amidolytic activity and antigen was detected in plasma from the proband. All the exons and intron/exon junctions of the protein C gene were studied using a strategy that combined polymerase chain reaction amplification with DNA sequencing of the amplified fragments. We identified a C-to-A change at nucleotide number 1387 of the protein C gene in the proband and his mother, and this mutant was designated protein C Osaka 10. The C-to-A change resulted in the substitution of Ser for Arg at position -1, which is the processing protease cleavage site. The mutant protein C was partially purified from plasma of the patient’s mother using barium adsorption followed by ion-exchange column chromatography. It eluted at the same sodium chloride concentration as normal protein C, and thus γ-carboxylation of the mutant protein appeared to be normal. The apparent molecular weight of this mutant protein C was the same as that of the normal protein on immunoblotting. Amino-terminal sequence analysis showed that the light chain of the mutant protein C had an additional Ser at position -1. Thus, the loss of anticoagulant activity of protein C Osaka 10 can be explained by alteration of the conformation of the Gla domain by the additional Ser in the mutant molecule.

• References

• 1 Stenflo J. A new vitamin K-dependent protein; Purification from bovine plasma and preliminary characterization. J Biol Chem 1976; 251: 355-363
• 2 Kisiel W, Ericsson LH, Davie EW. Proteolytic activation of protein C from bovine plasma. Biochemistry 1976; 15: 4893-900
• 3 Esmon CT. Protein-C: Biochemistry, physiology, and clinical implications. Blood 1983; 62: 1155-8
• 4 Foster D, Davie EW. Characterization of a cDNA coding for human protein C. Proc Natl Acad Sci USA 1984; 81: 4766-4770
• 5 Beckmann RJ, Schmidt RJ, Santerre RF, Plutzky J, Crabtree GR, Long GL. The structure and evolution of a 461 amino acid human protein C precursor and its messenger RNA, based upon the DNA sequence of cloned human liver cDNAs. Nucleic Acids Res 1985; 13: 5233-5247
• 6 Foster DC, Yoshitake S, Davie EW. The nucleotide sequence of the gene for human protein C. Proc Natl Acad Sci USA 1985; 82: 4673-4677
• 7 Plutzky J, Hoskins JA, Long GL, Crabtree GR. Evolution and organization of the human protein C gene. Proc Natl Acad Sci USA 1986; 83: 546-550
• 8 Foster DC, Rudinski MS, Schach BC, Berkner KL, Kumar AA, Hagen FS, Sprecher CA, Insley MY, Davie EW. Propeptide of human protein C is necessary for y-carboxylation. Biochemistry 1987; 26: 7003-7011
• 9 Kisiel W, Canfield WM, Ericsson LH, Davie EW. Anticoagulant properties of bovine plasma protein C following activation by thrombin. Biochemistry 1977; 16: 5824-5831
• 10 Vehar GA, Davie EW. Preparation and properties of bovine factor VIII (antihemophilic factor). Biochemistry 1980; 19: 401-410
• 11 Marlar RA, Kleiss AJ, Griffin JH. Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. Blood 1982; 59: 1067-1072
• 12 Soriano-Garcia M, Padmanabhan K, de Vos AM, Tulinsky A. The Ca²⁺ion and membrane binding structure of the Gla domain of Ca-prothrombin fragment 1. Biochemistry 1992; 31: 2554-2566
• 13 Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68: 1370-1373
• 14 Reitsma PH, Poort SR, Bemardi F, Gandrille S, Long GL, Sala N, Cooper DN. Protein C deficiency: A database of mutations. Thromb Haemost 1993; 69: 77-84
• 15 Miyata T, Zheng YZ, Sakata T, Tsushima N, Kato H. Three missense mutations in the protein C heavy chain causing type I and type II protein C deficiency. Thromb Haemost 1994; 71: 32-37
• 16 Shimamoto M, Yoshimura T, Kimura N, Kita M, Hoshino N, Motoi N, Suehisa E, Nishimura K, Hayashi C, Miyai K. Protein C in human plasma determined by homogeneous enzyme immunoassay with use of a centrifugal analyzer. Clin Chem 1988; 34: 1834-1838
• 17 Mimuro J, Sakata Y, Wakabayashi K, Matsuda M. Level of protein C determined by combined assays during disseminated intravascular coagulation and oral anticoagulation. Blood 1987; 69: 1704-1711
• 18 Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988; 239: 487-491
• 19 Zheng YZ, Sakata T, Matsusue T, Umeyama H, Kato H, Miyata T. Six missense mutations associated with type I and type II protein C deficiency and implications obtained from molecular modelling. Blood Coagul Fibrinolysis 1994; 5: 687-696
• 20 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685
• 21 Matsudaira P. Sequence from picomole quantities of proteins electro- blotted onto polyvinylidene difluoride membrane. J Biol Chem 1987 262: 10035-10038
• 22 Gandrille S, Alhenc-Gelas M, Gaussem P, Aillaud MF, Dupuy E, Juhan-Vague I, Aiach M. Five novel mutations located in exons III and IX of the protein C gene in patients presenting with defective protein C anticoagulant activity. Blood 1993; 82: 159-168
• 23 Girolami A, Simioni P, Girolami B, Marchiori A, Millar DS, Bignell P, Kakkar VV, Cooper DN. A novel dysfunctional protein C (Protein C Padua 2) associated with a thrombotic tendency: substitution of Cys for Arg-1 results in a strongly reduced affinity for binding of Ca⁺⁺ . Br J Haematol 1993; 85: 521-527
• 24 Ido M, Ohiwa M, Hayashi T, Nishioka J, Hatada T, Watanabe Y, Wada H, Shirakawa S, Suzuki K. A compound heterozygous protein C deficiency with a single nucleotide G deletion encoding Gly-381 and an amino acid substitution of Lys for Gla-26. Thromb Haemost 1993; 70: 636-641
• 25 Zhang L, Jhingan A, Castellino FJ. Role of individual y-carboxyglutamic acid residues of activated human protein C in defining its in vitro anticoagulant activity. Blood 1992; 80: 942-952
• 26 Welsch DJ, Nelsestuen GL. Amino-terminal alanine functions in a calcium- specific process essential for membrane binding by prothrombin fragment 1. Biochemistry 1988; 27: 4939-4945
• 27 McClure DB, Walls JD, Grinnell BW. Post-translational processing events in the secretion pathway of human protein C, a complex vitamin K-dependent antithrombotic factor. J Biol Chem 1992; 267: 19710-19717
• 28 Hoskins J, Norman DK, Beckmann RJ, Long GL. Cloning and characterization of human liver cDNA encoding a protein S precursor. Proc Natl Acad Sci USA 1987; 84: 349-353
• 29 Degen SJ F, MacGillivray RT A, Davie EW. Characterization of the complementary deoxyribonucleic acid and gene coding for human prothrombin. Biochemistry 1983; 22: 2087-2097
• 30 Hagen FS, Gray CL, O’Hara P, Grant FJ, Saari GC, Woodbury RG, Hart CE, Insley M, Kisiel W, Kurachi K, Davie EW. Characterization of a cDNA coding for human factor VII. Proc Natl Acad Sci USA 1986; 83: 2412-2416
• 31 Yoshitake S, Schach BG, Foster DC, Davie EW, Kurachi K. Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Biochemistry 1985; 24: 3736-3750
• 32 Leytus SP, Foster DC, Kurachi K, Davie EW. Gene for human factor X: A blood coagulation factor whose gene organization is essentially identical with that of factor IX and protein C. Biochemistry 1986; 25: 5098-5102
• 33 Diuguid DL, Rabiet MJ, Furie BC, Liebman HA, Furie B. Molecular basis of hemophilia B: A defective enzyme due to an unprocessed propeptide is caused by a point mutation in the factor IX precursor. Proc Natl Acad Sci USA 1986 83: 5803-5807
• 34 Bentley AK, Rees DJ G, Rizza C, Brownlee GG. Defective propeptide processing of blood clotting factor IX caused by mutation of arginine to glutamine at position -4. Cell 1986; 45: 343-348
• 35 Sugimoto M, Miyata T, Kawabata S, Yoshioka A, Fukui H, Iwanaga S. Factor IX Kawachinagano: Impaired function of the Gla-domain caused by attached propeptide region due to substitution of arginine by glutamine at position -4. Br J Haematol 1989; 72: 216-221
• 36 Watzke HH, Wallmark A, Hamaguchi N, Giardina P, Stafford DW, High KA. Factor X Santo Domingo: Evidence that the severe clinical phenotype arises from a mutation blocking secretion. J Clin Invest 1991; 88: 1685-1689
• 37 Gaussem P, Gandrille S, Duchemin J, Emmerich J, Alhenc-Gelas M, Aillaud MF, Aiach M. Influence of six mutations of the protein C gene on the Gla domain conformation and calcium affinity. Thromb Haemost 1994; 71: 748-754
• 38 Wu SM, Morris DP, Stafford DW. Identification and purification to near homogeneity of the vitamin K-dependent carboxylase. Proc Natl Acad Sci USA 1991; 88: 2236-2240